Cardiovascular Systems, Inc.
CSII · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.66 | -1.61 | 0.00 | -2.64 |
| FCF Yield | -1.03% | -2.61% | -1.92% | -0.33% |
| EV / EBITDA | -70.59 | -56.24 | -58.37 | -95.16 |
| Quality | ||||
| ROIC | -3.10% | -3.96% | -3.35% | -3.48% |
| Gross Margin | 69.96% | 72.02% | 73.97% | 73.69% |
| Cash Conversion Ratio | 0.45 | 1.28 | 1.01 | 0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.64% | 0.70% | -0.05% | -2.28% |
| Free Cash Flow Growth | 61.04% | -32.42% | -270.60% | -2.38% |
| Safety | ||||
| Net Debt / EBITDA | 5.60 | 4.59 | 5.19 | 5.27 |
| Interest Coverage | -21.11 | -26.85 | -23.30 | -23.64 |
| Efficiency | ||||
| Inventory Turnover | 0.45 | 0.44 | 0.47 | 0.45 |
| Cash Conversion Cycle | 176.43 | 174.91 | 168.80 | 172.67 |